NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $106.95, reflecting a -1.53% shift from the previouse trading day's closing. On the other hand, the Dow registered a loss of 0 ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Novo Nordisk's diabetes drug Ozempic has been linked to a rare and serious eye condition that can cause sudden and ...

Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations.

Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

Sydney Sweeney silenced internet trolls who criticized her body by sharing footage of her intense workout sessions—and the ...